NCT01385059View on ClinicalTrials.gov

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 28, 2011

Primary Completion Date

October 9, 2013

Study Completion Date

October 9, 2013

Conditions
Stage III Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

axitinib

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo prostatectomy and pelvic lymph node dissection

OTHER

enzyme-linked immunosorbent assay

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01385059 - Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter